CIMB Research: Bioalpha major shareholders undertaking to fully subscribe to rights issue is positive


KUALA LUMPUR: The move by Bioalpha Holdings Bhd major shareholders to subscribe to the health supplements maker’s latest rights issue is a positive one as it will ensure the rights shares will be fully subscribed.  

CIMB Research on Thursday said the company’s major shareholders, William Hon and PNS, have given an undertaking to subscribe for their portion of the rights issue shares. “In addition, Hon and PNS have also undertaken to subscribe for 16% and 56%, respectively, of the allocated rights issue not subscribed by minority shareholders. 

“This means, Hon and PNS have undertaken to subscribe for 100% of the proposed rights issue. We view this move positively as this ensures Bioalpha‘s proposed rights issue will be fully subscribed,’’ it added. 

Yesterday, the company had proposed 1-for-5 rights issue (one rights share for every five shares owned) and in addition would give one free warrant for every rights share subscribed. The issued share base would rise to 800 million shares, or 934 million shares assuming warrant conversion. Based on the indicative RM0.21 rights issue price, the company would raise around RM28mil cash.

Assuming the rights issue is set at RM0.21, this is at 25% discount to the estimated ex-rights issue price, the research house said, which it view fair as shareholders would also get a free warrant for very rights share subscribed. 

On a fully diluted basis, the issued share base would rise from 667 million to 934 million shares. Estimated 2017 earnings per share (EPS) dilution ex-rights issue is around 35%, it said, noting that the research house ex-rights target price (fully-diluted basis) would fall from RM0.52 to RM0.37.

CIMB said the proposed rights issue was a positive surprise as the proposed funds raised would be mainly used for planting 880 acres in Pasir Raja with herbs (RM10mil), and purchase of raw materials, packaging costs and working capital needs for new products (RM13.5mil). 

Bioalpha is planning to launch new products in all markets (China, Indonesia and Malaysia) over the next few months.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Nasdaq, S&P set to open higher on tech boost, earnings glee
Sasbadi reports highest ever quarterly revenue
Aneka Jaringan leverages order book for growth
Chin Hin Group to develop two lands with combined GDV of RM1.08bil
CLMT 1Q net profit rises to RM33.49mil on higher occupancies, positive rental reversions
Ringgit ends marginally lower on firmer US dollar index
MoF: Govt to establish high-level facilitation platform to oversee potential, approved strategic investments
Meta Bright signs RM24mil leasing contract with Australia company
OCR Group to develop RM313mil residential project in Rawang
Legacy Credit emerges as substantial shareholder in VCI Global

Others Also Read